(En anglais seulement.CB)
DR-TB DRUGS UNDER THE MICROSCOPE
SOURCES AND PRICES FOR DRUG-RESISTANT TUBERCULOSIS MEDICINES
3rd Edition October 2013
MSF et The Union
http://www.msfaccess.org/sites/default/files/MSF_TB_Report_UTM3rdEdition_20
13.pdf
Table of contents
Background
2 DR-TB drugs under the microscope
4 Sources and prices of DR-TB medicines: sluggish progress
11 R&D: breakthrough drugs offer new hopes, but significant research gaps
remain
15 What needs to happen
21 Methodology
Drug Profiles
Group two: Injectables
22 Amikacin
24 Kanamycin
26 Capreomycin
Group Thre: Fluoroquinolones
28 Moxifloxacin
30 Levofloxacin
32 Ofloxacin
Group Four: Oral bacteriostatic second-line agents
33 Ethionamide
34 Prothionamide
35 Cycloserine
37 Terizidone
38 PAS and PAS-sodium
Group five: Agents with unclear eficacy
40 Clofazimine
42 Linezolid
NEW DRUGS:
44 Bedaquiline
Annexes
46 Annex 1: Summary table of all prices
48 Annex 2: Conditions of offer, as quoted by companies
49 Annex 3: Company contacts
50 References
54 Glossary
56 Abbreviations